PIK3CB and breast carcinoma: Dual inhibitors of PI3K and mTOR, BEZ235 and PF-04691502, both demonstrated antitumor efficacy in breast cancer cells and xenograft models [252,253], but were also inclined to cause serious side effects in clinical practices.